
## Niraj C Patel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4146856/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. Journal of Allergy and Clinical Immunology, 2018, 142, 1665-1669.	2.9	196
2	A systematic analysis of recombination activity andÂgenotype-phenotype correlation in human recombination-activating gene 1 deficiency. Journal of Allergy and Clinical Immunology, 2014, 133, 1099-1108.e12.	2.9	132
3	Characterization of T and B cell repertoire diversity in patients with RAG deficiency. Science Immunology, 2016, 1, .	11.9	88
4	Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations. Journal of Allergy and Clinical Immunology, 2020, 146, 901-911.	2.9	78
5	Autosomal Dominant Hyper-IgE Syndrome in the USIDNET Registry. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 996-1001.	3.8	62
6	Mutations in topoisomerase Ill <sup>2</sup> result in a B cell immunodeficiency. Nature Communications, 2019, 10, 3644.	12.8	37
7	Scurvy Mimicking Osteomyelitis. Clinical Pediatrics, 2014, 53, 995-999.	0.8	30
8	Insights from American College of Allergy, Asthma, and Immunology COVID-19 Vaccine Task Force: Allergic Reactions to mRNA SARS-CoV-2 Vaccines. Annals of Allergy, Asthma and Immunology, 2021, 126, 319-320.	1.0	19
9	Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age. Journal of Clinical Immunology, 2015, 35, 558-565.	3.8	13
10	Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Two Infants. Journal of Clinical Immunology, 2012, 32, 474-476.	3.8	11
11	High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Advances, 2022, 6, 452-459.	5.2	11
12	Esophageal infections. Current Opinion in Pediatrics, 2015, 27, 642-648.	2.0	7
13	Individualized immunoglobulin treatment in pediatric patients with primary humoral immunodeficiency disease. Pediatric Allergy and Immunology, 2018, 29, 583-588.	2.6	6
14	Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study. Journal of Clinical Immunology, 2021, 41, 458-469.	3.8	4
15	Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study. Journal of Clinical Immunology, 2021, 41, 66-75.	3.8	3
16	Photo Quiz: A 9-Year-Old Girl with Eye Swelling and Drainage. Journal of Clinical Microbiology, 2018, 56, .	3.9	2
17	The economic implications of penicillin allergy. Annals of Allergy, Asthma and Immunology, 2020, 125, 626-627.	1.0	2
18	Answer to April 2018 Photo Quiz. Journal of Clinical Microbiology, 2018, 56, .	3.9	1

#	Article	IF	CITATIONS
19	Subcutaneous Immunoglobulin Therapy with IgPro20 in Patients with Stiff Person Syndrome and Primary Immunodeficiency Disease. Journal of Neuromuscular Diseases, 2021, 8, 973-977.	2.6	1